MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.05
-0.05 (-0.28%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.10
Open18.14
Bid0.00 x 4000
Ask0.00 x 800
Day's Range17.77 - 18.23
52 Week Range16.63 - 39.59
Volume4,202,505
Avg. Volume7,756,952
Market Cap9.304B
Beta (3Y Monthly)2.10
PE Ratio (TTM)39.24
EPS (TTM)0.46
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est28.28
Trade prices are not sourced from all markets
  • GlobeNewswire8 days ago

    Mapi Pharma to Build a New Sterile Injectable Production Plant for GA Depot in Jerusalem

    Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term lease agreement at the Har-Hotzvim Hi-Tech Park in Jerusalem for the establishment of a new sterile production plant for GA Depot injectable products. The ~50,000 square foot plant was previously part of Omrix Biopharmaceuticals, Inc., a Johnson & Johnson Company, and was an FDA-approved facility. The new leased area will be used for commissioning a commercial scale production facility for GA Depot and is a scale-up to the current Israeli Ministry of Health (MOH) GMP approved facility the Company operates to supply the ongoing clinical trials (Phase II, III).

  • Amneal (AMRX) Down on Guidance Update & Restructuring Plan
    Zacks12 days ago

    Amneal (AMRX) Down on Guidance Update & Restructuring Plan

    Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.

  • ‘There’s Nothing to Give Them’: The Hunt for Lifesaving Epipens
    Bloomberg13 days ago

    ‘There’s Nothing to Give Them’: The Hunt for Lifesaving Epipens

    (Bloomberg) -- A persistent shortage of Mylan NV’s EpiPen anti-allergy injectors is forcing patients and pharmacists to go to great lengths to get their hands on the lifesaving device.EpiPens, which can help stop a severe or life-threatening allergic reaction, have been hard to get since at least May 2018, when the Food and Drug Administration said the device was in short supply. While other options are available, including an identical lower-priced version of the device from Mylan, consumers have also struggled to secure alternatives thanks to uneven distribution, the reluctance of insurers to pay for similar treatments and uneasiness with unfamiliar products.Even patients who live near numerous pharmacies have been scrambling. Boston resident Justin Klaassen said he drove 45 minutes outside the city earlier this year to find EpiPens for his 7-year-old daughter. Everywhere he called within 10 miles of Boston was out of stock of the device, which carries a list price of more than $600 for a two-pack but has been scarce because of manufacturing problems.“My family has enough money to buy one with insurance, you know, and even two because you want one at school and you want one at home,” Klaassen said. “But there are families out there who can’t even afford one, and then you have the problem finding them.”EpiPens can be especially difficult to track down at the start of a new school year, when sales tend to peak. Teachers and staff in school districts across the U.S. have been trained to use the devices, while few have been shown how to use rivals like Adrenaclick and Auvi-Q. Some parents say that they worry that the few moments needed to get familiar with a new injector could be costly in an emergency.Pharmacists are racing to keep EpiPens on their shelves, scooping up fresh supply whenever they can. Ashley Seyfarth, the owner of New Mexico pharmacy Kare Drug, said she “plays the back-order game,” ordering from her wholesaler as soon as a shipment comes in regardless of whether she has prescriptions that need immediate filling.Steps taken by U.S. regulators in recent weeks suggest that they expect the deficit of EpiPen brand injectors to linger, meaning more headaches likely await parents of students returning to school next month. In June, the FDA said expiration dates for some devices would be extended by four months.Mylan has been providing information about EpiPen production and distribution shortages to the FDA on a weekly basis, said agency spokesman Nathan Arnold. The FDA can’t say when the shortage will end, he said.“The FDA looks at drug shortages on a national scale,” Arnold said. “There may be local shortages in any given area of the United States even when there are not national shortages."Mylan shares declined as much as 5.4% on Wednesday, the largest intraday decline in more than a month. So far this year, the drugmaker’s stock price has fallen by 32%.The current problems finding EpiPens can be traced back to September 2017, when Pfizer Inc.’s Meridian Medical Technologies division, which makes them for Mylan, received a warning from the FDA after allegedly failing to investigate hundreds of complaints about faulty devices.Pfizer spokeswoman Kim Bencker said the company is also frustrated by the unsteady supply and that EpiPens involve a “highly complex and technical” manufacturing process.“Despite our significant efforts, we do anticipate further supply shortages over the coming months,” Bencker said. “Product is routinely shipping, and we are committed to permanently resolving this availability issue as quickly as possible.”Mylan spokeswoman Lauren Kashtan said the company is sending shipments as soon as it receives the product from Meridian and encourages people to call customer relations for assistance in locating alternative pharmacies. The generic injector made by Mylan isn’t offically in shortage, according to the FDA.Production problems have also vexed makers of competing injectors. Amneal Pharmaceuticals Inc. lowered its earnings guidance for 2019 on Wednesday due in part to uncertainty about supplies of its generic version of Adrenaclick.Shares of the company declined as much as 37%, the steepest intraday decline since May 2010. Amneal’s product is also manufactured by Pfizer’s Meridian unit, Amneal spokesman David Belian said.Inventory IssuesPharmacists say that nailing down when they can get more EpiPens has been difficult. Carter High, owner of Best Value Rhome Pharmacy in Texas, said his wholesaler has pushed back the date when more injectors would be available several times.“As a parent, I look at that and think, God I wish I could help them,” High said. “I can’t. There’s nothing to give them because I just can’t get it.”High said he has also had difficulty obtaining Mylan’s generic EpiPens. At times, he said he gave patients epinephrine, the drug delivered by a shot from Mylan’s device, the “old-school way,” with a syringe. He said he tells patients to keep expired EpiPens because it’s “better to have something than nothing.”In the meantime, brand-name EpiPen prescriptions have swooned. After peaking at more than 580,000 in August 2016, there were just 27,000 in May 2019, according to data compiled by Bloomberg Intelligence.Going without an EpiPen can be dangerous for patients like Ashley Spencer, 29. She was eating a strawberry when she went into anaphylaxis on June 23. Her skin was bright red and itchy. Her throat was closing.Spencer, who suffers from a rare autoimmune disease, didn’t have an EpiPen. She’d been waiting for a refill for more than a week when her body developed the new allergy.“I can’t go a week and a half without it because my disease also can cause me to go into anaphylaxis at any time,” Spencer said. EpiPens “are crucial to my life.”“As a parent, I look at that and think, God I wish I could help them...There’s nothing to give them because I just can’t get it.”Insurance companies have sometimes balked at paying for pricier alternatives. High, the Texas pharmacist, said wholesalers “have plenty of Auvi-Q, but at $5,000 a whack, I can’t even get insurance to pay for that.” While some large pharmacy chains have struck agreements with EpiPen competitors to try to alleviate the shortage and reduce patients costs, others have struggled to get insurers to pay for alternatives.“Though there are other things out there, we can’t use them even if we can get our hands on them,” said Seyfarth, the pharmacist in New Mexico.Additionally, a new generic made by Teva Pharmaceutical Industries Ltd. has been difficult to track down, pharmacists say. “I’ve never actually seen Teva’s product in the marketplace,” said Hamilton, New Jersey, pharmacist Eklavya Lalwani.In an earnings call in May, Teva Chief Executive Officer Kare Schultz said the company is “ramping up the volumes” and is distributing its injector to Anda Inc., a supplier the drugmaker owns. “Any pharmacy who needs EpiPen can just call Anda, and they will get it within 24 hours,” Schultz said in May.Teva spokeswoman Kelley Dougherty said the company has no backorders for the product, but both High and Lalwani said it was indicated as out of stock in Anda’s ordering system on July 8.Elsewhere, Sandoz, a division of Swiss drug giant Novartis AG, said on Tuesday that Symjepi epinephrine injections, previously only given in hospitals and clinics, will now be available at pharmacies.Even when insurance covers another brand, some parents like Klaassen, in Boston, have trained their family and friends on Mylan’s device and don’t want to switch. Others such as Erin Malawer, who lives near Washington, switched her 14-year-old son to Auvi-Q but still tries to find at least one EpiPen, because she fears that his friends or teachers might not recognize an alternative device in an emergency.“If you’re looking for an EpiPen, blue and orange tube, and it’s not there, you’re wasting precious seconds that could save a life,” Malawer said.(Updates with Amneal Pharmaceuticals comment in the 17th paragraph.)To contact the author of this story: Myah Ward in New York at mward174@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today
    Motley Fool13 days ago

    Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today

    Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.

  • Why Mylan Isn’t Having a Great July
    Market Realist14 days ago

    Why Mylan Isn’t Having a Great July

    Let's see how Mylan, a US generic pharmaceutical company that's taken a heavy beating this year, is positioned in July.

  • GlobeNewswire28 days ago

    Medexus Appoints Accomplished Global Pharmaceutical Industry Executive Adele M. Gulfo to its Board of Directors

    Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), a leading specialty pharmaceutical company with a strong North American commercial platform, announces that Adele M. Gulfo has joined the Company's Board of Directors, further enhancing the Board’s commercial and business development expertise. Ken d’Entremont, Chief Executive Officer of Medexus, commented, “We are thrilled to add Adele to our Board of Directors.

  • Mylan (MYL) Down 18.8% Since Last Earnings Report: Can It Rebound?
    Zacks2 months ago

    Mylan (MYL) Down 18.8% Since Last Earnings Report: Can It Rebound?

    Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Teva Settles With Oklahoma, Shares Fall Following Downgrade
    Zacks2 months ago

    Teva Settles With Oklahoma, Shares Fall Following Downgrade

    Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.

  • Options Traders Expect Huge Moves in Mylan (MYL) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in Mylan (MYL) Stock

    Investors need to pay close attention to Mylan (MYL) stock based on the movements in the options market lately.

  • Barrons.com2 months ago

    The 5 Worst Stocks So Far This Year

    FEATURE (CTL) Memorial Day is behind us, and with it the unofficial start of summer. And as we approach the midway point of 2019, it’s a good time to take stock of how stocks are doing. Here’s a look at the five companies with the worst-performing stocks in the S&P 500 this year through last week.

  • Amgen (AMGN) Offers to Acquire Drug Discovery Platform
    Zacks2 months ago

    Amgen (AMGN) Offers to Acquire Drug Discovery Platform

    Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MYL earnings conference call or presentation 7-May-19 2:00pm GMT

    Q1 2019 Mylan NV Earnings Call

  • The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

  • AbbVie Settles Humira Litigation With Boehringer Ingelheim
    Zacks2 months ago

    AbbVie Settles Humira Litigation With Boehringer Ingelheim

    AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

  • Here's Why Generic-Drug Manufacturers Were Down Monday
    Motley Fool2 months ago

    Here's Why Generic-Drug Manufacturers Were Down Monday

    Forty-four states have brought a lawsuit against the industry.

  • Generic Drugmakers Face Antitrust Suit Alleging Price Fixing
    Zacks2 months ago

    Generic Drugmakers Face Antitrust Suit Alleging Price Fixing

    Shares of generic drugmakers decline on allegations of price fixing by 44 states.

  • Mylan Reiterates 2019 Revenue Guidance for These Segments
    Market Realist2 months ago

    Mylan Reiterates 2019 Revenue Guidance for These Segments

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidance for Europe and Rest of World In the first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance in the mid-single

  • Barrons.com2 months ago

    The Dow Plunges 617 Points Because China Is Hitting Back With Retaliatory Tariffs

    News of China’s retaliatory tariffs sent shares tumbling. The Dow Jones Industrial Average lost 2.38% to close at 25,324.99. The S&P 500 has dropped 2.41% to finish at 2811.87, and the Nasdaq Composite dropped 3.41% to close at 7647.02.

  • Barrons.com2 months ago

    2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

    Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.

  • Mylan Reiterated 2019 Revenue Growth Guidance for North America
    Market Realist2 months ago

    Mylan Reiterated 2019 Revenue Growth Guidance for North America

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)North America revenue growth trendsDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance of high-single-digits for its

  • A Look at Mylan’s Expense Guidance in Fiscal 2019
    Market Realist2 months ago

    A Look at Mylan’s Expense Guidance in Fiscal 2019

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Expense guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its guidance for fiscal 2019 SG&A (selling, general, and administrative) expenses to

  • What to Expect from Mylan’s Gross Margin and EBITDA
    Market Realist2 months ago

    What to Expect from Mylan’s Gross Margin and EBITDA

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Gross margin guidanceAt the Raymond James 40th Annual Institutional Investors Conference, Mylan (MYL) guided for an adjusted gross margin of 53.0% to 54.0% for fiscal 2019, a

  • Mylan Reiterated Fiscal 2019 Adjusted EPS Guidance
    Market Realist2 months ago

    Mylan Reiterated Fiscal 2019 Adjusted EPS Guidance

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Adjusted EPS guidanceDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed fiscal 2019 adjusted EPS guidance of $3.80 to $4.80, which would be a decline of

  • Mylan Reiterated Fiscal 2019 Revenue Guidance
    Market Realist2 months ago

    Mylan Reiterated Fiscal 2019 Revenue Guidance

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its fiscal 2019 revenue guidance of $11.5 billion to $12.5 billion. The company expects to